First, Fra-1 and c-Fos overexpression in breast tumor tissues in comparison with undetectable levels in normal tissue confers per se high tumorigenic tissue specificity because the deletion mutants will interfere only with the activity of these proteins in cells overexpressing their full-length versions. This evidence concerns the gene FOSL1 and breast neoplasm.